Clinical Trial Update: Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating whether saxagliptin reduces cardiovascular events in people with type 2 diabetes, either alone or with other medications; the study is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Onglyza (Saxagliptin)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes Mellitus | Phase 4 | Status: COMPLETED | Results posted: 2014-06-13